TOKYO, Feb 2 (Reuters) - Japanese drugmaker Astellas Pharma Inc said its $1 billion bid for U.S. biotechnology firm CV Therapeutics Inc is its best offer, ruling out the possibility of sweetening its bid for now.
TOKYO, Feb 2 (Reuters) - Japanese drugmaker Astellas Pharma Inc said its $1 billion bid for U.S. biotechnology firm CV Therapeutics Inc is its best offer, ruling out the possibility of sweetening its bid for now.
